MAAT.PA Maat Pharma SA
- Market cap
- EUR 20.5M
- P/E
- -
- P/B
- 10.67x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is MAAT.PA undervalued?
Graham numberThe Graham number of Maat Pharma SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Maat Pharma SA fundamental analysis
3 of 11 checks passedROE 0/2
Negative ROE (-41.61%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-31.87%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 1/2
The stock's PBV ratio (2.84x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.
DER 2/2
The stock has a low debt to equity ratio (42%), which means it has a small amount of debt compared to the ownership it holds
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.
Assets Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Graham Number 1/1
The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.
Dividend Growth 0/2
Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.
Dividend 0/2
The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.
Buffet Intrinsic Value 0/1
The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Maat Pharma SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic…
Full company profileMaat Pharma SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Maat Pharma SA annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 109K | 892K | 89.3K | 0.00 | 972K | 1.43M | 2.23M | 3.22M | 4.52M | 4.32M |
| Gross Profit | -3.39M | 813K | -7.70K | -164K | 806K | 1.09M | 784K | 1.97M | 1.39M | 3.90M |
| Operating Income | -4.71M | -4.40M | -4.97M | -7.39M | -8.89M | -13.6M | -19.9M | -28.4M | -34.2M | -84.2M |
| EBITDA | -4.66M | -5.09M | -6.08M | -6.58M | -8.57M | -13.1M | -22.1M | -26.3M | -32.4M | -68.6M |
| Net Income | -3.86M | -4.55M | -6.65M | -5.35M | -9.02M | -13.7M | -19.7M | -28.9M | -31.1M | -73.3M |
| EPS | -3.74 | -4.40 | -32 | -26 | -3.72 | -1.39 | -1.73 | -2.21 | -1.95 | -3.89 |
| Balance Sheet | ||||||||||
| Total Assets | 9.26M | 5.89M | 8.17M | 24.3M | 49.4M | 44.7M | 42.9M | 38.5M | 44.6M | 34.2M |
| Total Liabilities | 3.99M | 4.62M | 12.7M | 8.34M | 9.56M | 17.9M | 22.5M | 28.2M | 42.8M | 50.4M |
| Shareholders' Equity | 5.27M | 1.27M | -4.57M | 15.9M | 39.9M | 26.8M | 20.5M | 10.3M | 1.80M | -16.2M |
| Cash & Short-term Investments | 7.35M | 3.60M | 5.41M | 19.9M | 43.3M | 35.3M | 24.3M | 20.2M | 24.9M | 17.1M |
| Total Debt | 1.72M | 2.60M | 10.5M | 6.08M | 5.81M | 11.4M | 14.1M | 16.0M | 17.4M | 23.8M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.87M | -3.87M | -5.02M | -5.81M | -7.93M | -12.6M | -18.7M | -22.0M | -15.9M | -60.7M |
| Capital Expenditure | 291K | 291K | 128K | 316K | 238K | 662K | 1.09M | 753K | 609K | 188K |
| Free Cash Flow | - | -4.16M | -5.15M | -6.13M | -8.17M | -13.3M | -19.8M | -22.8M | -16.5M | -60.9M |
| Ratios | ||||||||||
| ROE | -73.2% | -358.2% | - | -33.6% | -22.6% | -51.1% | -96.3% | -279.6% | -1,726.6% | - |
| ROA | -41.7% | -77.2% | -81.4% | -22.0% | -18.2% | -30.7% | -45.9% | -75.1% | -69.7% | -214.5% |
| Net Profit Margin | -3,529.5% | -509.6% | -7,443.1% | - | -927.9% | -959.0% | -885.0% | -898.8% | -686.6% | -1,698.9% |
| Debt to Equity | 0.33x | 2.05x | - | 0.38x | 0.15x | 0.42x | 0.69x | 1.54x | 9.69x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Maat Pharma SA dividends
Maat Pharma SA has not paid dividends in the last 9 fiscal years.
Who owns Maat Pharma SA
- Insiders 22.06%
- Institutions 46.78%
- Public & others 31.16%
- Shares outstanding 18.8M
- Free float 11.0M
Maat Pharma SA company profile
- Company name
- Maat Pharma SA
- Ticker
- MAAT.PA
- ISIN
- FR0012634822
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 60
- Fiscal year end
- December
- Address
- 70 Avenue Tony Garnier, Lyon, France, 69007
- Phone
- 33 4 28 29 14 00
- Website
- maatpharma.com
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. MaaT Pharma SA was incorporated in 2014 and is headquartered in Lyon, France.
Maat Pharma SA management
10- Mr. Herve AffagardCEO, Co-Founder & Director · born 1974
- Dr. Joel Dore Ph.D.Co-Founder & Member of Scientific Advisory Board
- Mr. Pierre RimbaudCo-Founder
- Mr. Eric Soyer Ph.D.Chief Financial Officer · born 1966
- Ms. Carole SchwintnerTechnology Director & Chief Technology Officer
- Ms. Sheri Simmons Ph.D.Acting Chief Scientific Officer
- Guilhaume Debroas Ph.D.Head of Investor Relations
- Dr. Frederic Fasano M.B.A., Pharm.D.Chief Strategy & Corporate Development Officer · born 1968
- Ms. Sian CrouzetChief of Staff
- Dr. Emilie Plantamura Ph.D., Pharm.D.Deputy Chief Medical Officer